SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000947871-20-000602
Filing Date
2020-07-07
Accepted
2020-07-06 17:57:01
Documents
2
Group Members
ORBIMED CAPITAL GP VII LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss177336_sc13d.htm SC 13D 115323
2 JOINT FILING AGREEMENT ss177336_ex9901.htm EX-99.1 6340
  Complete submission text file 0000947871-20-000602.txt   123221
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Subject) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91552 | Film No.: 201014514
SIC: 2836 Biological Products, (No Diagnostic Substances)